Uncategorized
Ophthotech Announces First Patient Dosed in Zimura® Phase 2/3 Study to Evaluate Treatment in Patients with Geographic Atrophy, an Advanced Form of Dry Age-Related Macular Degeneration
NEW YORK--(BUSINESS WIRE)--Ophthotech Corporation announced that the first patient has been dosed in a Phase 2/3 clinical study of Zimura® (avacincaptad pegol sodium).
